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Microtubule active taxanes inhibit polycystic kidney disease
progression in cpk mice
DAVID D.L. Woo, ANGEL P. TABANCAY, JR., and CAROLYN J.N. WG
Microtubule active taxanes inhibit polycystic kidney disease progres-
sion in epic mice. Homozygous cpklcpk mice develop polycystic kidney
disease and die of uremia between the fourth and fifth weeks of age.
Cpklcpk mice treated weekly with paclitaxel (Taxol) can live to over six
months of age. This dramatic moderation of polycystic kidney disease
progression has been postulated to be a result of paclitaxel's ability to
stabilize microtubules. In this study, the ability of taxanes with differing
abilities to promote spontaneous in vitro assembly of tubulin dimers into
microtubules were tested for their ability to inhibit the progression of
polycystic kidney disease in polycystic cpklcpk mice. We found that taxanes
that are active in promoting microtubule assembly, including paclitaxel,
lO-deactyl-taxol and cephalomannine increased the survival of polycystic
cpk/cpk mice significantly longer than control animals. In contrast, the
microtubule inactive taxane baccatin-Ill has no effect on the progression
of renal failure in cpk/cpk mice. We conclude that the ability to promote
microtubule assembly may be necessary for paclitaxel and related taxanes
to modulate the progression of polycystic kidney progression in cpk/cpk
mice.
The polycystic kidney diseases (PKD) are a group of systemic
disorders characterized by the presence of bilaterally enlarged
kidneys where normal renal tissues are replaced with fibrotic
tissues and with thousands of fluid-filled cysts [1]. In human, the
diseases can be inherited in autosomal dominant (ADPKD) or
autosomal recessive (ARPKD) forms. ADPKD is the most com-
mon, dominantly inherited kidney disease of humans, occurring at
a frequency of about 1 in 800. ARPKD occurs at a rare frequency
of about 1 in 10,000. Clinically, PKD represents a major cause of
end-stage renal disease. Microdissection, histochemical and im-
munologic studies showed that cysts in ARPKD kidneys arise
from focal dilations of medullaty collecting ducts [2]. Mutations in
at least three different loci have been associated with ADPKD in
humans. These include PKD1 on chromosome 16 [3—5], PKD2 on
chromosome 4 [6, 7] and the not yet mapped PKD3. The ARPKD
mutation has recently mapped to chromosome 6 in the human [8,
9]. The molecular and cellular mechanisms leading to the initial
development and subsequent progression of the renal and extra-
renal manifestation of polycystic kidney disease are not com-
pletely understood.
The spontaneous murine polycystic kidney disease mutation,
cpk, [10, 11] has been mapped to mouse chromosome 12 [12, 13].
Kidney abnormalities and disease progression in C57BL16-cpk/cpk
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mice have been studied in detail [11, 141. Afected animals have
microscopic dilations of their proximal renal tubules at birth but
otherwise appear normal. The enlarged tubules rapidly expend
into cysts. Between 10 to 13 days of age, homozygous cpklcpk
animals can be recognized by protuberant abdomens resulting
from greatly enlarged kidneys. Affected kidneys weight almost
2.0 g at day 24 compared with about 0.18 g for age-matched
normal kidneys. Concomitant with kidney enlargement, there is a
dramatic apoptotic loss of non-cystic kidney tissues [15, 16] and
progressive deterioration of kidney functions. Polycystic cpklcpk
mice become progressively lethargic and die by 28 to 35 days of
age due to renal failure.
Characteristic features of cystic changes in epithelia from
human polycystic kidney such as cellular hyperplasia and abnor-
mal basement membrane are observed in renal cysts of cpk/cpk
mice [17]. The accumulation of fluid in cysts indicates abnormal
fluid transport in cpk cystic epithelia. The presence of altered
expression of basement membrane components [18, 19], altered
growth controlling gene expression [20—221, altered targeting of
the normally basolaterally Na-K ATPase [23] and EGF receptor
[24], and expression of developmentally dedifferentiated pheno-
types [25] have made the cpk mouse a widely used animal model
for studying the diverse renal pathobiologies of polycystic kidney
disease.
Paclitaxel (taxol) is a diterpenoid natural product originally
isolated from the Pacific yew tree, Taxus brevifolia, and represents
the prototype compound of a class of new antineoplastic drugs
that act by stabilizing microtubules. Interestingly, paclitaxel has
recently been shown to significantly inhibit the progression of
polycystic kidney disease and dramatically prolong the survival of
polycystic cpklcpk mice [26]. Since other antiproliferative drugs,
including cytosine arabinoside and methotrexate [26], have no
effect on the progression of polycystic kidney disease in cpk mice,
the effect of paclitaxel on the progression of polycystic kidney
disease in cpklcpk mice is probably not a direct result of its
antiproliferative effects [26]. Instead of dying of azotemia by the
fourth to fifth week of age, polycystic cpklcpk mice treated weekly
with paclitaxel can survive to over six months of age [26]. A major
biological activity of paclitaxel is mediated by its ability to bind to
microtubules and to promote the spontaneous in vitro polymer-
ization of tubulin subunits into microtubules [27]. To determine if
the microtubule assembling ability of paclitaxel and related tax-
anes plays a direct role in modulating the progression of polycystic
kidney disease, we studied the effect of systemic administration of
selected taxanes with different microtubule activities on the
progression of polycystic kidney disease in cpk/cpk mice.
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Fig. 1. Progressive apoptotic loss of renal tissues in cpk/cpk kidneys. Typical histological sections of the polycystic kidneys from day 7 (A), day 9 (B) and
day 28 (C) cpk/cpk mice are illustrated. Before day 7, gross apoptotic loss of renal tissues is primarily limited to the cortical-medullary zone (A). By days
8 to 9 renal apoptosis spread to the renal cortex (B). Apoptosis persists in cystic epithelia after day 9 but are masked by excessive cellular proliferation.
Consequently, progressive cystic expansion occurs throughout the kidney, and polycystic cpk/cpk kidneys became palpable after day 10.
Methods
Animals
Heterozygous C57BL16-cpkl+ breeder mice were purchased
from the Jackson Laboratory (Bar Harbor, ME, USA). Our cpk
mouse colony was maintained by mating known heterozygotes.
Mice were kept with their mothers until they were weaned at 28
days of age. All studies involving animals were approved by
UCLA's Chancellor's Animal Research Committee.
Paclitaxel, cephalomannine, JO-deactyl-taxol and baccatin-Ill
treatment
Paclitaxel was a gift from the National Cancer Institute. Cepha-
lomannine, 10-deacetyl-taxol and baccatin-Ill were purchased
from Hauser Chemical (Boulder, CO, USA). All taxanes used in
this study were dissolved at 10 mg!ml in dimethyl sulfoxide
(DMSO) and were stored frozen at —20°C in aliquots until used.
Beginning on day 7 after birth, the entire litter of mice from
selected matings were injected every other week interperitoneally
with 5 .d of the selected taxane (10 mg/mI). After day 10, only
mice with palpable polycystic kidneys continued to receive treat-
ment. All polycystic mice were treated continually for the duration
of their life. Animals similarly treated with dimethyl sulfoxide and
untreated animals were used as controls.
1-listology
At the indicated times, animals were sacrificed, their organs
fixed overnight in 10% neutral buffercd formalin (Fisher Scien-
tific, Pittsburgh, PA, USA) and embedded in paraffin. Five micron
sections were stained with periodic acid-Schiff stain and counter-
stained with hematoxylin.
Determination of renal function
Animals were sacrificed by cervical dislocation at the indicated
age. Blood (0.5 ml) was collected from the aorta. Serum creatinine
was measured in triplicate using a commercial creatinine kit
(Sigma Chemical Company, St. Louis, MO, USA) with the
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Fig. 2. Effect of taxanes on the survival of cpklcpk mice. A. The survival of
20 DMSO treated cpk/cpk mice (thick line) is compared to the survival of
25 untreated cpk/cpk (thin line) mice. The survival of paclitaxel (B, N =
43), 10-deacetyl taxol (C, N = 13), cephalomannine (D, N = 12) and
baccatin-TH (E, N = 7) treated cpklcpk mice (thick line) are compared to
DMSO-treated cpk/cpk mice (thin line).
following modifications. Hemolysis of serum interfered strongly
with the creatinine assay. Hemoglobin in serum samples (100 pd)
was precipitated with TCA at a final concentration of 10% in 1.5
ml centrifuge tubes. Precipitated proteins were removed by
centrifugation at 13,000 rpm for 10 minutes. The de-proteined
serum was neutralized to pH 7.0 with NaOH. Creatinine deter-
mination was carried out with 25 pJ of the neutralized de-
proteined serum in flat-bottom rigid microtiter plates according to
the creatinine assay kit's directions, but scaled down to a 250 j.d
assay volume. Absorbance before and after addition of the acid
reagent was recorded at 490 nm using a Molecular Device VMax
96 well plate reader (Molecular Devices, Menlo Park, CA, USA).
Results
The progression of polycystic disease in cpklcpk mice is char-
acterized by rapid enlargement of hundreds of renal cysts within
the affected kidneys. Concurrent with the expansion of these cysts
is the rapid apoptotic loss of non-cystic nephrons [15, 161. Direct
histological examination of kidneys from seven-day-old polycystic
mice showed that about 30% of the non-cystic nephrons near the
medullary-cortical junction is already missing (Fig. 1A). By day 8
to day 9, apoptotic loss of nephrons have spread to and advance
along the cortical zone (Fig. 1B). Renal apoptosis persists in cystic
epithelia after day 9 but are masked by excessive cellular prolif-
eration. Virtually all the remaining non-cystic nephrons in un-
treated cpklcpk mice are completely lost by the time the animals
die at four to five weeks of age (Fig. IC). During this last phase of
the disease, enormous expansion in cyst volume and proliferation
of cystic epithelial cells occurs (Fig. 1C).
Because a large fraction of nephrons has already been lost in
polycystic cpk mice by the time enlarged kidneys can be palpated
at day 10, we reasoned that a greater benefit might be obtained by
initiating the experiment earlier. All experimental taxane treat-
ments were therefore initiated on day 7 by giving the agents to the
entire litter. Despite treatment, the kidneys of all treated polycys-
tic cpk mice continued to enlarge and become palpable by day 10.
The kidneys of mice without palpably enlarged kidneys by day 10
to day 13 were all histologically normal (data not shown).
Paclitaxe4 cephalomannine and lO-deacetyl-taxol prolonged
survival of polycystic cpk mice
Figure 2A compared the survival of 20 polycystic cpk/cpk mice
treated weekly with 5 j.rl of DMSO and the survival of 25
untreated polycystic cpk/cpk mice. There was no statistically
significant difference between the survival of vehicle treated and
untreated controls (log-rank chi-square = 3.45; P = 0.06). Figure
2B compared the survival of 43 polycystic cpklcpk mice given
weekly paclitaxel and the survival of 20 DMSO polycystic cpklcpk
mice. Over 60% of paclitaxel-treated polycystic cpk/cpk mice
survived past 40 days of age, and almost 40% of paclitaxel treated
mice survived past 100 days of age. In contrast, only one of the
DMSO polycystic cpklcpk mice lived to 42 days of age. Statisti-
cally, the difference in survival between control and paclitaxel
treated animals was highly significant (log-rank chi-square = 12.8,
P = 0.003). The average serum creatinine of three 90-day-old and
active polycystic cpklcpk mice treated with paclitaxel was 3.1 0.6
mg/dl (vs. 6.2 0.7 mg/dl in DMSO-treated 24-day-old mice and
0.6 mg/dl in normal mice).
The survival of lO-deacetyl-taxol treated polycystic cpk mice
was also significantly longer than DMSO treated cpk/cpk mice
(Fig. 2C; log-rank chi-square = 22.39, P < 0.0001). The average
serum creatinine of six 90-day-old and active polycystic cpk/cpk
mice treated with lO-deacetyl-taxol was 2.5 0.3 mg/dl.
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Fig. 3. Comparative mo,phology of normal mouse kidney, paclitaxel treated cpklcpk kidney and untreated cpklcpk kidney. Compared to the normal adult
mouse kidney with approximately a hundred thousand nephrons (A) and the almost complete absence of nephrons in 28-day-old end-stage cpk/cpk
kidney (C), the polycystic kidneys of cpk/cpk mice treated weekly with paclitaxel (B) contained significant numbers of surviving nephrons after 120 days.
Cells lining the remnant nephrons are all much larger in size indicating they have all hypertrophied (arrowheads). Significant interstitial fibrosis has also
developed (arrows). Bar = 0.1 CM.
The survival of cephalomannine treated polycystic cpk/cpk mice
was significantly longer than DMSO treated cpk/cpk mice (log-
rank chi-square = 14.11,P = 0.0002; Fig. 2D). The average serum
creatinine of six 90-day-old and active polycystic cpk/cpk mice
treated with cephalomannine was 2.3 0.4 mgfdl.
Baccatin-IJI has no effect on the survival of polycystic cpk mice
In contrast to the significant increase in the survival of
polycystic cpk/cpk mice treated with paclitaxel, cephaloman-
nine or lO-deactyl-taxol, the survival of polycystic cpk/cpk mice
treated with baccatin-Ill was not statistically different from
DMSO treated cpk!cpk mice (log-rank chi-square 1.56; p =
0.21; Fig. 2E). Although higher doses of baccatin-lIl (100 and
200 xg/animal/weck; N = 8 for each of these doses) were not
toxic to the treated animals, no significant effect were observed
on the survival of polycystic cpk mice treated at these doses
(data not shown).
Moiphology of paclitaxel and microtubule-active taxane treated
kidneys. The histological appearances and relative sizes of a
four-month-old normal adult mouse kidney (Fig. 3A) and a
four-month-old taxol-treated polycystic cpk/cpk kidney (Fig. 3B)
are shown in relation to a 28-day-old azotemic polycystic cpklcpk
kidney (Fig. 3C). Polycystic kidneys obtained from apparently
healthy polycystic cpklcpk mice treated weekly with taxol for 120
days are significantly smaller in size (diameter = 0.6 0.17 cm;
N = 6) than untreated polycystic kidneys from cpk/cpk mice
(diameter = 1.2 0.2 cm; N = 6). In addition, kidneys from the
paclitaxel-treated polycystic cpklcpk mice have fewer and smaller
cysts than kidneys from untreated or DMSO treated polycystic
cpk/cpk mice (Fig. 3B). In comparison to a normal adult mouse
kidney, which typically contains about a hundred thousand
nephrons, and to end-stage kidneys of untreated cpk/cpk mice
where very few remnant nephrons can be found, histologic
examination revealed the presence of a significant number of
greatly hypertrophied nephrons in kidneys from the paclitaxel
treated mice (Fig. 3B). Significant interstitial fibrosis was also
observed in the polycystic kidneys of all treated cpklcpk mice
surviving past 60 days of age (Fig. 3B). Kidneys from all the
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Table 1. Side-chain structures, microtubule assembling activities and cytotoxicity of selected taxanes (excerpted from Burkhart et al [33] and
Parness Ct al [32])
Name R1 R2 R3 % MT activity Cytotoxicity pM
Baccatin HI HO— AcO— —OH < 0.01 > 20
Paclitaxel
ONH(51
AcO— —OH 100 0.05
10-Deacetyltaxol
QNH -
HO— —OH 105 0.30
Cephatomannine
-
AcO— —OH 100 0.15
microtubule-active taxane-treated polycystic cpklcpk mice all resem-
bled kidneys from polycystic cpklcpk mice treated weekly with
paclitaxel for the same length of time by both gross and histological
criteria (data not shown).
Discussion
The structural requirements for the in vitro microtubule assem-
bly activity of taxanes has been examined in detail by studying
synthetic analogs of paclitaxel [28—31]. However, none of these
synthetic taxanes are available to us in quantities sufficient for in
vivo studies in mice. Along with paclitaxel, several closely related
and naturally occurring taxanes are present in the bark of the
Pacific yew tree. The microtubule assembly promoting activities of
these naturally occurring taxanes have been characterized in
detail [32]. Several of these taxanes have recently become avail-
able commercially in pure form. The structural relationship
between the taxanes selected for this study are listed in Table 1.
Paclitaxel has two complete ring structures at the C-13 side-chain.
Cephalomannine has one complete and one partial ring structure
at the C-13 side-chain. lO-Deactyl-taxol lacks an acetyl group at
the C-lu position. When compared to paclitaxel, both cephalo-
mannine and lO-deacetyl-taxol are 100% as active as paclitaxel in
promoting in vitro microtubule assembly, but are only 50% and
30% as cytotoxic as paclitaxel [331. Baccatin-lIl lacks the C-13
side-chain and is not active in microtubule assembly assay [331.
In this study, we showed that the abilities of the taxanes to
suppress the progression of polycystic kidney disease are com-
pletely correlated with their known abilities to bind to and
promote spontaneous assembly of microtubules in vitro. The
microtubule assembly active taxanes including paclitaxel, cepha-
lomannine and lO-deactyl-taxol are all active in prolonging the
survival of polycystic cpklcpk mice, while the inactive baccatin-Ill
has no effect on the progression of polycystic kidney disease in
these mice. These results support the hypothesis that the micro-
tubule cytoskeleton may play important roles in the progression of
polycystic disease in cpk/cpk mice. The presence of significant
numbers of life-sustaining hypertrophied nephrons in the kidneys
of all the successfully treated cpklcpk mice suggests that as a result
of the taxane treatments, these nephrons have avoided apoptotic
death and survived.
Recent studies showed that besides its microtubule stabilizing
effects, paclitaxel has significant lipopolysaccharide (LPS)-like
activities [34, 35]. For example, paclitaxel has been shown to
induce the expression of tumor necrosis factor-a (TNF-a) [33, 35,
36], interleukin-113 [3537J p2lwAFl and p53 [38] and the "early"
LPS-inducible genes, IP-lO, D3, D7 and D8 [36]. In addition,
paclitaxel can cause a reduction in the surface expression of
TNF-a receptors [34], induces tyrosine phosphorylation of micro-
tubule-associated protein kinases (also known as mitogen-acti-
vated protein kinases or MAP kinases [36, 37, 39, 40]), and
activates NF-KB [41].
These observations also suggest that paclitaxel and the micro-
tubule active taxanes may exert their inhibitory effect on the
progression of polycystic kidney disease in cpk/cpk mice by
binding to and signaling via the microtubule cytoskeleton. Be-
cause of the dramatic effect that microtubule-active taxanes have
on the survival of polycystic cpklcpk mice, further research will be
required to determine the roles of these taxanes and the micro-
tubule cytoskeleton on the apoptotic death of nephrons and on
the progression of polycystic kidney disease in cpk!cpk mice.
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